<DOC>
	<DOCNO>NCT00824655</DOCNO>
	<brief_summary>The purpose study evaluate safety 13-valent pneumococcal Conjugate Vaccine ( 13vPnC ) child already vaccinate Prevenar . The study also assess immunological response ( measure amount antibody , i.e . protein fight germ ) produce child give 13-valent pneumococcal vaccine 5 12 month 12 month age . In addition , reaction injection site assess study .</brief_summary>
	<brief_title>Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Healthy Children</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy child previously immunize 1 2 dos Prevenar . Group 1 : Male female subject age &gt; =140 &lt; =196 day age time enrollment . Group 2 : Male female subject age &gt; =336 &lt; =392 day age time enrollment Available entire study period . Previous reaction contraindication pneumococcal vaccine vaccine relate component . Previous vaccination license investigational pneumococcal vaccine Prevenar .</criteria>
	<gender>All</gender>
	<minimum_age>140 Days</minimum_age>
	<maximum_age>392 Days</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Healthy Subjects</keyword>
	<keyword>Vaccines</keyword>
	<keyword>Pneumococcal</keyword>
</DOC>